Mr. Gaslightwala serves as President and CEO of Akari Therapeutics since April 21, 2025 and as Director since December 2024. He is a well-established leader in the biotechnology and pharmaceutical industry. He has a successful track record spanning over 25 years in the development and commercialization of novel medicines across a range of companies and therapeutic areas, and in particular the Oncology therapeutic area over the last 10 years. Mr. Gaslightwala most recently served as the Senior Vice President and Franchise Head for Oncology at Jazz Pharmaceuticals, where he managed a portfolio of products spanning both solid tumors and hematological malignancies generating up to $1B in annual sales.
Mr. Gaslightwala has also been in several leadership roles at Amgen, Pfizer, and Johnson & Johnson, where he has led development, launch, and growth of several products within Oncology and other therapeutics areas. His experiences at these leading companies spanned business unit leadership, brand marketing, sales leadership, commercial pipeline planning, advanced analytics and insights, and business development. Prior to these roles, Mr. Gaslightwala advised several life science companies through his time at the Boston Consulting Group (BCG).
Mr. Gaslightwala holds a BS in Chemical Engineering from Cornell University, and an MBA from the Sloan School of Management, and a MS in Chemical Engineering from MIT.
What is Abizer Gaslightwala's net worth?
The estimated net worth of Abizer Gaslightwala is at least $60.82 thousand as of August 21st, 2025. Mr. Gaslightwala owns 7,189 shares of Akari Therapeutics stock worth more than $60,819 as of October 2nd. This net worth approximation does not reflect any other assets that Mr. Gaslightwala may own. Learn More about Abizer Gaslightwala's net worth.
How do I contact Abizer Gaslightwala?
Has Abizer Gaslightwala been buying or selling shares of Akari Therapeutics?
Abizer Gaslightwala has not been actively trading shares of Akari Therapeutics within the last three months. Most recently, on Monday, August 25th, Abizer Gaslightwala bought 75 shares of Akari Therapeutics stock. The stock was acquired at an average cost of $36.00 per share, with a total value of $2,700.00. Following the completion of the transaction, the chief executive officer now directly owns 7,464 shares of the company's stock, valued at $268,704. Learn More on Abizer Gaslightwala's trading history.
